Trial 57:

"<br> **Inclusion Criteria**:<br><br> - Healthy volunteer male and female participants between 18 to 65 years of age<br><br> - Body Mass Index (BMI) of 17.5 to 32 kg/m2; and a total body weight >50 kg (110 lb)<br><br> **Exclusion Criteria**:<br><br> - Evidence or history of clinically significant hematological, renal, endocrine,<br> pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or<br> allergic disease (including drug allergies, but excluding untreated, asymptomatic,<br> seasonal allergies at the time of dosing).<br><br> - Evidence of active, latent, or inadequately treated infection with Mycobacterium<br> tuberculosis<br><br> - Participants with acute or chronic infections or infection history<br><br> - History of human immunodeficiency virus (HIV); Infection with hepatitis B or hepatitis<br> C viruses according to protocol specific testing algorithm<br><br> - History of febrile illness within 5 days prior to the first dose of investigational<br> product.<br><br> - Recent exposure to live or attenuated vaccines within 28 days of the screening visit.<br><br> - Failure to comply with coronavirus disease 2019 (COVID-19) vaccination requirements as<br> per site protocols.<br><br> - Have any malignancies or have a history of malignancies with the exception of<br> adequately treated or excised non-metastatic basal cell or squamous cell cancer of the<br> skin, or cervical carcinoma in situ.<br><br> - History of any lymphoproliferative disorder such as Epstein-Barr Virus (EBV) related<br> lymphoproliferative disorder, history of lymphoma, leukemia, or signs and symptoms<br> suggestive of current lymphatic or lymphoid tissue disease.<br><br> - Undergone significant trauma or major surgery within 1 month of the first dose of<br> study drug<br><br> - Previous administration with an investigational product (drug or vaccine) within 30<br> days (or as determined by the local requirement) or 5 half-lives preceding the first<br> dose of study intervention used in this study (whichever is longer)<br><br> - Screening supine blood pressure (BP) =140 mm Hg (systolic) or =90 mm Hg (diastolic),<br> following at least 5 minutes of supine rest<br><br> - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level =1.5 × Upper<br> limit of normal (ULN);<br><br> - Total bilirubin level =1.5 × ULN; participants with a history of Gilbert's syndrome<br> may have direct bilirubin measured and would be eligible for this study provided the<br> direct bilirubin level is =ULN.<br><br> - estimated glomerular filtration rate (eGFR) =75 mL/min/1.73 m2 based on chronic kidney<br> disease epidemiology (CKD-EPI) equation<br><br> - History of alcohol abuse or binge drinking and/or any other illicit drug use or<br> dependence within 6 months of Screening<br><br> - Participants with more than 5 cigarettes per day or =10 pack years<br><br> - Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more<br> within 60 days prior to dosing<br> "